Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'MAO INHIBITION' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 27 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Weinstock, M; Goren, T; Youdim, MBH
      Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities

      DRUG DEVELOPMENT RESEARCH
    2. Arai, Y; Yasuhara, H; Hamamichi, N; Toyofuku, H; Tadano, T; Kisara, K; Kinemuchi, H
      Inhibition of rat brain monoamine oxidase activity by two analogues of clorgyline

      BIOGENIC AMINES
    3. Bonnet, U; Leniger, T; Wiemann, M
      Moclobemide reduces intracellular pH and neuronal activity of CA3 neuronesin guinea-pig hippocampal slices - implication for its neuroprotective properties

      NEUROPHARMACOLOGY
    4. Speiser, Z; Mayk, A; Eliash, S; Cohen, S
      Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemiain the rat

      JOURNAL OF NEURAL TRANSMISSION
    5. Knoll, J; Yoneda, F; Knoll, B; Ohde, H; Miklya, I
      (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain

      BRITISH JOURNAL OF PHARMACOLOGY
    6. DOMINO EF
      TOBACCO SMOKING AND NICOTINE NEUROPSYCHOPHARMACOLOGY - SOME FUTURE-RESEARCH DIRECTIONS

      Neuropsychopharmacology
    7. Avramova, P; Danchev, N; Buyukliev, R; Bogoslovova, T
      Synthesis, toxicological, and pharmacological assessment of derivatives of2-aryl-4-(3-arylpropyl)morpholines

      ARCHIV DER PHARMAZIE
    8. MAHMOOD I
      IS 10 MILLIGRAMS SELEGILINE ESSENTIAL AS AN ADJUNCT THERAPY FOR THE SYMPTOMATIC TREATMENT OF PARKINSONS-DISEASE

      Therapeutic drug monitoring
    9. SOTOOTERO R; MENDEZALVAREZ E; RIGUERAVEGA R; QUINOACABANA E; SANCHEZSELLERO I; LAMAS MLR
      STUDIES ON THE INTERACTION BETWEEN 1,2,3,4-TETRAHYDRO-BETA-CARBOLINE AND CIGARETTE-SMOKE - A POTENTIAL MECHANISM OF NEUROPROTECTION FOR PARKINSONS-DISEASE

      Brain research
    10. DINGEMANSE J; WOOD N; JORGA K; KETTLER R
      PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE DOSES OFTHE MAO-B INHIBITOR LAZABEMIDE IN HEALTHY-SUBJECTS

      British journal of clinical pharmacology
    11. WOUTERS J; OOMS F; JEGHAM S; KOENIG JJ; GEORGE P; DURANT F
      REVERSIBLE INHIBITION OF TYPE-B MONOAMINE-OXIDASE - THEORETICAL-STUDYOF MODEL DIAZO HETEROCYLIC COMPOUNDS

      European journal of medicinal chemistry
    12. MENDEZALVAREZ E; SOTOOTERO R; SANCHEZSELLERO I; LAMAS MLR
      INHIBITION OF BRAIN MONOAMINE-OXIDASE BY ADDUCTS OF 1,2,3,4-TETRAHYDROISOQUINOLINE WITH COMPONENTS OF CIGARETTE-SMOKE

      Life sciences
    13. FRIEDGEN B; WOLFEL R; RUSS H; SCHOMIG E; GRAEFE KH
      THE ROLE OF EXTRANEURONAL AMINE TRANSPORT-SYSTEMS FOR THE REMOVAL OF EXTRACELLULAR CATECHOLAMINES IN THE RABBIT

      Naunyn-Schmiedeberg's archives of pharmacology
    14. FRIEDGEN B; WOLFEL R; GRAEFE KH
      THE CONTRIBUTION BY MONOAMINE-OXIDASE AND CATECHOL-O-METHYLTRANSFERASE TO THE TOTAL-BODY AND PULMONARY PLASMA-CLEARANCE OF CATECHOLAMINES

      Naunyn-Schmiedeberg's archives of pharmacology
    15. TADANO T; NEDA M; HOZUMI M; YONEZAWA A; ARAI Y; FUJITA T; KINEMUCHI H; KISARA K
      ALPHA-METHYLATED TRYPTAMINE DERIVATIVES INDUCE A 5-HT RECEPTOR-MEDIATED HEAD-TWITCH RESPONSE IN MICE

      Neuropharmacology
    16. GUENTERT TW; HOLFORD NHG; PFEFEN JP; DINGEMANSE J
      MIXED LINEAR AND NONLINEAR DISPOSITION OF LAZABEMIDE, A REVERSIBLE AND SELECTIVE INHIBITOR OF MONOAMINE-OXIDASE-B

      British journal of clinical pharmacology
    17. HOLFORD NHG; GUENTERT TW; DINGEMANSE J; KETTLER R
      PHARMACODYNAMICS OF LAZABEMIDE, A REVERSIBLE AND SELECTIVE INHIBITOR OF MONOAMINE-OXIDASE-B

      British journal of clinical pharmacology
    18. HOLFORD NHG; GUENTERT TW; DINGEMANSE J; BANKEN L
      MONOAMINE OXIDASE-A - PHARMACODYNAMICS IN HUMANS OF MOCLOBEMIDE, A REVERSIBLE AND SELECTIVE INHIBITOR

      British journal of clinical pharmacology
    19. ROCHA L; MARSTON A; KAPLAN MAC; STOECKLIEVANS H; THULL U; TESTA B; HOSTETTMANN K
      AN ANTIFUNGAL GAMMA-PYRONE AND XANTHONES WITH MONOAMINE-OXIDASE INHIBITORY ACTIVITY FROM HYPERICUM BRASILIENSE

      Phytochemistry
    20. OLANOW CW
      A RATIONALE FOR MONOAMINE-OXIDASE INHIBITION AS NEUROPROTECTIVE THERAPY FOR PARKINSONS-DISEASE

      Movement disorders
    21. HOLTJE HD; WALPER A
      MOLECULAR MODELING OF THE ANTIDEPRESSIVE MECHANISM OF HYPERICUM INGREDIENTS

      Nervenheilkunde
    22. HAEFELY W; BURKARD WP; CESURA A; COLZI A; KETTLER R; LOREZ HP; MARTIN JR; MOREAU JL; RICHARDS JG; SCHAFFNER R; SCHERSCHLICHT R; SEPINWALL J; DAPRADA M
      PHARMACOLOGY OF MOCLOBEMIDE

      Clinical neuropharmacology
    23. MULLER T; KUHN W; PRZUNTEK H
      THERAPY WITH CENTRAL ACTIVE CATECHOL-O-METHYLTRANSFERASE (COMT)-INHIBITORS - IS ADDITION OF MONOAMINE-OXIDASE (MAO)-INHIBITORS NECESSARY TOSLOW PROGRESS OF NEURODEGENERATIVE DISORDERS

      Journal of neural transmission
    24. HEDEEN KM; WHITE HL; COOPER BR; CONNER GW; NORTON RM
      EFFECT OF A NOVEL MONOAMINE OXIDASE-A INHIBITOR, BW 1370U87, ON URINARY 3-METHOXY-4-HYDROXYPHENYLGLYCOL IN NORMAL VOLUNTEERS

      Drug development research
    25. ALEVIZOS B; HATZIMANOLIS J; MARKIANOS M; STEFANIS CN
      CLINICAL, ENDOCRINE AND NEUROCHEMICAL EFFECTS OF MOCLOBEMIDE IN DEPRESSED-PATIENTS

      Acta psychiatrica Scandinavica
    26. HARRELSON JC; JOHNSON TE; WHITE HL; WELCH RM
      METABOLISM OF BW-1370U87 IN RAT, DOG, AND MAN

      Drug development research
    27. NORTON RM; WHITE HL; COOPER BR
      METABOLISM OF BW-1370U87 BY CRUDE LIVER HOMOGENATES FROM SEVERAL SPECIES - AN INVITRO METHOD FOR PRELIMINARY INVESTIGATION OF SPECIES-DIFFERENCES IN METABOLISM

      Drug development research


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/08/20 alle ore 01:27:22